The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...